Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
6 Financial plan 3D Printers with the Best Worth - 2Empathy and reasoning aren’t rivals – new research shows they work together to drive people to help more
- 3Manual for Tracking down Spending plan Agreeable Travel Objections
- 4Find Wonderful Stream Voyage Objections On the planet
- 5Schools to start reopening after Nigeria mass abduction
- What to know about cheese voluntarily recalled in 20 states
- Figure out How to Pick a SUV with Senior-Accommodating Tech Elements
- How to watch the last supermoon of the year
- The wolf supermoon will kick off 2026 with a celestial bang. Here's when and how to see it.
- RFK Jr. releases new dietary guidelines with emphasis on protein, full-fat dairy
- How much would you pay to meet a Real Housewife? At BravoCon, the limit does not exist.
- The hunt for dark matter: a trivia quiz
- Startled Venezuelans express relief but also fear after Maduro arrest
- Decrease in Home Buy Credits and Home loan Renegotiating Rates: An Outline of Latest things
